Human umbilical cord plasma concentrate
Human umbilical cord plasma concentrate has been studied in 1 paper since 2022: 1 trial in people. The newest paper, Sep 2, 2022: “Umbilical cord plasma concentrate has beneficial effects on DNA methylation GrimAge and human clinical biomarkers”.
1 paper studies it7 findingsUpdated
See all 1 papers on human umbilical cord plasma concentrate
At a glance
The findings reach people, from one lab or study. 1 lab in 1 country.
“AgeAccelGrim was significantly decreased from 0.04 to −0.78 (paired Student's t‐test p = 9.3E‐3).”
None of its findings points the other way.
- 1 lab in 1 country
- Funder: National Institute on Aging
- 7 of 7 findings with company ties
- Human trial1
Studies in people
1 study gave human umbilical cord plasma concentrate to people and measured what changed.
| What changed | Design | People | Source |
|---|---|---|---|
down: Decreases GrimAgefrom 0.04 to −0.78 down: Decreases creatinine up: Increases estimated glomerular filtration rate | Trial10 weeks | 18 people10 women and 8 menaverage age of 74 (range 60 to 95)Older adults considered to be in normal health for their ages | Aging cell, Sep 2, 2022 |
What did studies of human umbilical cord plasma concentrate find?
6Studies of human umbilical cord plasma concentrate measured 6 outcomes, among them GrimAge, telomere length and epigenetic clocks estimating chronological age.
GrimAge
downin humans1
1 study
GrimAge
downin humans1
Human umbilical cord plasma concentrate decreases GrimAge in humans (-0.82 years).
“The treatment reduced DNA methylation-based GrimAge by an average of 0.82 years (p = 0.0093)”
Human trial1 ml intramuscular weekly10 weeksn = 18
Aging cell
Human umbilical cord plasma concentrate decreases GrimAge in humans (from 0.04 to −0.78).
“AgeAccelGrim was significantly decreased from 0.04 to −0.78 (paired Student's t‐test p = 9.3E‐3).”
Human trial10 weeksn = 18
Aging cell
Telomere length
no changein humans1
1 study
Telomere length
no changein humans1
Human umbilical cord plasma concentrate showed no clear effect on telomere length in humans.
“telomere length and mtDNA-CN were not significantly affected by the treatment”
Human trial1 ml intramuscular weekly10 weeksn = 18
Aging cell
Epigenetic clocks estimating chronological age
no changein humans1
1 study
Epigenetic clocks estimating chronological age
no changein humans1
Human umbilical cord plasma concentrate showed no clear effect on epigenetic clocks estimating chronological age in humans.
“By contrast, no significant results could be observed for epigenetic clocks that estimate chronological age.”
Human trial1 ml intramuscular weekly10 weeksn = 18
Aging cell
Immunoglobulins
downin humans1
1 study
Immunoglobulins
downin humans1
Human umbilical cord plasma concentrate decreases immunoglobulins in humans.
“Three of four immunoglobulin biomarkers decreased”
Human trial1 ml intramuscular weekly10 weeksn = 18
Aging cell
Estimated glomerular filtration rate
upin humans1
1 study
Estimated glomerular filtration rate
upin humans1
Human umbilical cord plasma concentrate increases estimated glomerular filtration rate in humans.
“estimated glomerular filtration rate (eGFR) was increased (p = 0.0044)”
Human trial1 ml intramuscular weekly10 weeksn = 18
Aging cell
Creatinine
downin humans1
1 study
Creatinine
downin humans1
Human umbilical cord plasma concentrate decreases creatinine in humans.
“Specifically, creatinine level decreased after the treatment (p = 3.9E‐3) and eGFR values increased (p = 4.4E‐3).”
Human trial10 weeksn = 18
Aging cell